Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
Nephrol Dial Transplant. 2010 Sep;25(9):2839-43. doi: 10.1093/ndt/gfq324. Epub 2010 Jun 13.
The nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is a rare, recently recognized disorder in water balance affecting not only infants but also adults. A new molecular mechanism responsible for NSIAD has recently been identified: a gain of function of the arginine vasopressin (AVP) receptor type 2 (V2R), causing the constitutive activation of the receptor. Clinical presentation and laboratory findings of NSIAD resemble those of the syndrome of inappropriate secretion of antidiuretic hormone and consist of hyponatraemia, seizures and the lack of urinary dilution; however, the AVP levels in plasma are undetectable or very low. An elucidation of the pathophysiology of this syndrome will provide more insight into the action of AVP. An effective treatment of NSIAD is available. It consists of fluid restriction and administration of oral urea. Reported experience with furosemide treatment in NSIAD is still lacking.
肾源性尿崩症(NSIAD)是一种罕见的、最近才被认识的水平衡紊乱疾病,不仅影响婴儿,也影响成人。最近发现了一种导致 NSIAD 的新的分子机制:精氨酸加压素(AVP)受体 2 型(V2R)的功能获得,导致受体的组成性激活。NSIAD 的临床表现和实验室检查结果与抗利尿激素分泌不当综合征相似,包括低钠血症、癫痫发作和尿不稀释;然而,血浆中的 AVP 水平检测不到或非常低。对该综合征病理生理学的阐明将使人们对 AVP 的作用有更深入的了解。NSIAD 的有效治疗方法是限制液体摄入和口服尿素。在 NSIAD 中使用呋塞米治疗的经验报告仍然缺乏。